PF-06821497 Behandlung von rezidiviertem/refraktärem SCLC, kastrationsresistentem Prostatakrebs und follikulärem Lymphom
EINE PHASE-I-DOSEESSKALATION UND ERWEITERTE KOHORTSTUDIE VON PF-06821497 ZUR BEHANDLUNG VON ERWACHSENEN PATIENTEN MIT REZITIERTEM/REFRAKTÄREM KLEINZELLIGEM LUNGENKREBS (SCLC), KASTRATIONRESISTENTEM PROSTATAKREBS (CRPC) UND FOLLIKULÄREM LYMPHOM (FL)
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL). The study consists of 3 parts; Part 1 and 2 enrolled participants with SCLC, metastatic CRPC, and FL are closed for enrollment.
Part 3, which is open for enrollment is seeking men who:
- have Castration Resistant Prostate Cancer (CRPC) and
- have previously received treatment for CRPC and have progressed from the last treatment
All participants in Part 3 of this study will receive mevrometostat and/ or enzalutamide. Part 3 consists of 2 sub studies each has an assessment phase and a maintenance phase. The Part 3 DDI substudy consist of 2 cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (Combination cohort).
In the assessment phase:
- participants in the BE substudy will take 3 single doses of mevrometostat by mouth over 3 periods.
- participants in the DDI substudy Cohort 1 (monotherapy cohort) will take mevrometostat 2 times a day and/or itraconazole 1 time a day based on a present schedule.
- participants in the DDI substudy Cohort 2 (combination cohort) will take mevrometostat 2 times a day, enzalutamide 1 time a day, and/or itraconazole 1 time a day based on a present schedule.
After completion of the assessment phase, participants will enter the maintenance phase where they will receive mevrometostat 2 times a day and enzalutamide 1 time a day by mouth until their cancer is no longer responding.
The study will look at the experiences of participanrs receiving the study medicine. This will help see if the study medicine is safe and effective.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
This is an open label, multi center, Phase 1 dose escalation and dose expansion study of mevrometostat (PF-06821497) administered orally BID as a single agent or in combination with SOC to patients with CRPC, SCLC, and FL. The study consists of three parts (Part 1, Part 2, and Part 3) along with the Japan and China monotherapy cohorts. Part 1 and Part 2 are closed for enrollment. Part 1 tested monotherapy in 3 cohorts (Parts 1A, 1B, and 1C); Part 2 tested combination therapy in Parts 2A (dose escalation), 2B and 2C (does expansion).
Part 3 consists of the Bioequivalence (BE) and drug-drug interaction (DDI) substudies and are open for enrollment. The BE substudy will test between 2 mevrometostat formulation to confirm that they work in the body the same way. The DDI substudy will evaluate the effect of a strong CYP3A4 (an enzyme in your body that breaks down/ removes drugs) inhibitor on the PK of mevrometostat; a strong CYP3A4 inhibitor may slow down the breakdown/ removal of drugs in your body. The Sponsor may choose to delay or discontinue any cohorts or substudies.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Pfizer CT.gov Call Center
- Telefonnummer: 1-800-718-1021
- E-Mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studienorte
-
-
-
Haskovo, Bulgarien, 6300
- Beendet
- Specialized Hospital for Active Treatment of Oncology - Haskovo
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Aktiv, nicht rekrutierend
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Hunan
-
Changsha, Hunan, China, 410013
- Aktiv, nicht rekrutierend
- Hunan Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Aktiv, nicht rekrutierend
- Zhongda Hospital Southeast University
-
Nanjing, Jiangsu, China, 210008
- Aktiv, nicht rekrutierend
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Rekrutierung
- West China Hospital, Sichuan University
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Aktiv, nicht rekrutierend
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
Chiba
-
Kashiwa, Chiba, Japan, 277-8577
- Aktiv, nicht rekrutierend
- National Cancer Center Hospital East
-
-
-
-
-
Bydgoszcz, Polen, 85-048
- Noch keine Rekrutierung
- In-Vivo Sp. z o.o. In-vivo Bydgoszcz
-
Koszalin, Polen, 75-581
- Aktiv, nicht rekrutierend
- Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie
-
Krakow, Polen, 30-348
- Rekrutierung
- Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
-
Rzeszów, Polen, 35-326
- Aktiv, nicht rekrutierend
- Centrum Medyczne MEDYK
-
Warsaw, Polen, 02-781
- Aktiv, nicht rekrutierend
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
-
-
-
-
-
Moscow, Russland, 117186
- Aktiv, nicht rekrutierend
- LLC "Neyro-klinika"
-
Moscow, Russland, 125284
- Beendet
- Moscow GBUZ "City clinical hospital n. a. S.P. Botkina" of Moscow health department
-
Moscow, Russland, 129301
- Beendet
- SBHI of Moscow City Clinical Hospital
-
Omsk, Russland, 644013
- Beendet
- Budgetary Healthcare Institution of Omsk region "Clinical Oncological Dispensary"
-
Saint Petersburg, Russland, 197341
- Beendet
- Federal State Budgetary Institution National Medical Research Center n.a. V.A. Almazov
-
Saint Petersburg, Russland, 197758
- Beendet
- Federal State Budgetary Institution National Medical Research Center for Oncology n.a. N.N.
-
Saint Petersburg, Russland, 198255
- Beendet
- Saint Petersburg State Budgetary Healthcare Institution "City Clinical Oncological Dispensary"
-
Yaroslavl, Russland, 150054
- Beendet
- State Budgetary Healthcare Institution of the Yaroslavl Region
-
-
Sankt-Peterburg
-
Pushkin, Sankt-Peterburg, Russland, 196603
- Aktiv, nicht rekrutierend
- Private Medical Institution "Euromedservice"
-
-
-
-
-
Barcelona, Spanien, 08035
- Rekrutierung
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spanien, 08036
- Rekrutierung
- Hospital Clinic de Barcelona
-
Barcelona, Spanien, 08023
- Rekrutierung
- Hospital Quironsalud Barcelona
-
Madrid, Spanien, 28034
- Rekrutierung
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28050
- Rekrutierung
- Hospital Universitario HM Sanchinarro
-
Madrid, Spanien, 28040
- Rekrutierung
- H.U. Fundación Jiménez Díaz
-
Madrid, Spanien, 28041
- Rekrutierung
- Hospital Universitario 12 De Octubre
-
Málaga, Spanien, 29010
- Rekrutierung
- Hospital Universitario Virgen de la Victoria
-
Valencia, Spanien, 46026
- Aktiv, nicht rekrutierend
- Hospital Universitari i Politecnic La Fe
-
-
Barecelona
-
L'Hospitalet de Llobregat, Barecelona, Spanien, 08908
- Aktiv, nicht rekrutierend
- Institut Català d´Oncología (ICO)-H. Durán i Reynals
-
-
Castellon
-
Castellon, Castellon, Spanien, 12002
- Aktiv, nicht rekrutierend
- Consorcio Hospitalario Provincial de Castellon
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spanien, 28223
- Rekrutierung
- Hospital Quironsalud Madrid
-
-
Madrid, Comunidad de
-
Madrid, Madrid, Comunidad de, Spanien, 28040
- Rekrutierung
- Hospital Clinico San Carlos
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Südkorea, 13620
- Rekrutierung
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [seoul]
-
Seoul, Seoul-teukbyeolsi [seoul], Südkorea, 03080
- Aktiv, nicht rekrutierend
- Seoul National University Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Südkorea, 07985
- Aktiv, nicht rekrutierend
- Ewha Womans University Mokdong Hospital
-
Seoul, Seoul-teukbyeolsi [seoul], Südkorea, 03722
- Aktiv, nicht rekrutierend
- Severance Hospital, Yonsei University Health System
-
-
Taejǒn-kwangyǒkshi
-
Daejeon, Taejǒn-kwangyǒkshi, Südkorea, 35015
- Aktiv, nicht rekrutierend
- Chungnam national university hospital
-
-
-
-
Arizona
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Aktiv, nicht rekrutierend
- Banner-University Medical Center Tucson
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Aktiv, nicht rekrutierend
- The University of Arizona Cancer Center-North Campus
-
Tucson, Arizona, Vereinigte Staaten, 85724
- Aktiv, nicht rekrutierend
- The University of Arizona Cancer Center
-
Tucson, Arizona, Vereinigte Staaten, 85741
- Beendet
- Arizona Urology Specialists, PLLC
-
-
California
-
Anaheim, California, Vereinigte Staaten, 92801
- Aktiv, nicht rekrutierend
- Pacific Cancer Medical Center INC
-
Duarte, California, Vereinigte Staaten, 91010
- Aktiv, nicht rekrutierend
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
-
Duarte, California, Vereinigte Staaten, 91010
- Aktiv, nicht rekrutierend
- City of Hope Investigational Drug Services (IDS)
-
-
Connecticut
-
Norwalk, Connecticut, Vereinigte Staaten, 06856
- Aktiv, nicht rekrutierend
- Norwalk Hospital
-
-
Kansas
-
Fairway, Kansas, Vereinigte Staaten, 66205
- Aktiv, nicht rekrutierend
- The University of Kansas Cancer Center, Investigational Drug Services
-
Fairway, Kansas, Vereinigte Staaten, 66205
- Aktiv, nicht rekrutierend
- The University of Kansas Clinical Research Center
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Aktiv, nicht rekrutierend
- The University of Kansas Hospital
-
Kansas City, Kansas, Vereinigte Staaten, 66160
- Aktiv, nicht rekrutierend
- The University of Kansas Medical Center Medical Office Building
-
Overland Park, Kansas, Vereinigte Staaten, 66211
- Aktiv, nicht rekrutierend
- The University of Kansas Cancer Center - Indian Creek Campus
-
Westwood, Kansas, Vereinigte Staaten, 66205
- Aktiv, nicht rekrutierend
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Aktiv, nicht rekrutierend
- Norton Cancer Institute, Norton Healthcare Pavilion
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Aktiv, nicht rekrutierend
- Norton Hospital
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Aktiv, nicht rekrutierend
- Norton Cancer Institute - Downtown
-
-
Maryland
-
Rockville, Maryland, Vereinigte Staaten, 20850
- Beendet
- Maryland Oncology Hematology, P.A.
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Aktiv, nicht rekrutierend
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Aktiv, nicht rekrutierend
- Brigham and Women's Hospital
-
Newton, Massachusetts, Vereinigte Staaten, 02459
- Aktiv, nicht rekrutierend
- Dana Farber Cancer Institute- Chestnut Hill
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68130
- Rekrutierung
- Oncology Hematology West, PC dba Nebraska Cancer Specialists
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Aktiv, nicht rekrutierend
- Hackensack University Medical Center
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Aktiv, nicht rekrutierend
- John Theurer Cancer Center at Hackensack University Medical Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- OU Health University of Oklahoma Medical Center
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- Stephenson Cancer Center (chemo location)
-
-
South Carolina
-
Myrtle Beach, South Carolina, Vereinigte Staaten, 29572
- Rekrutierung
- Carolina Urologic Research Center
-
Myrtle Beach, South Carolina, Vereinigte Staaten, 29572
- Rekrutierung
- Parkway Surgery Center
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- Sarah Cannon Research Institute - Pharmacy
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78705
- Beendet
- Texas Oncology - Austin Midtown
-
Dallas, Texas, Vereinigte Staaten, 75390
- Aktiv, nicht rekrutierend
- UT Southwestern Medical Center
-
Dallas, Texas, Vereinigte Staaten, 75390
- Aktiv, nicht rekrutierend
- University of Texas Southwestern Medical Center - Simmons Cancer Center
-
Dallas, Texas, Vereinigte Staaten, 75390
- Aktiv, nicht rekrutierend
- UT Southwestern University Hospital - William P. Clements, Jr
-
Dallas, Texas, Vereinigte Staaten, 75390
- Aktiv, nicht rekrutierend
- UT Southwestern University Hospital - Zale Lipshy
-
Irving, Texas, Vereinigte Staaten, 75063
- Beendet
- US Oncology Investigational Product Center (IPC)
-
Irving, Texas, Vereinigte Staaten, 75063
- Beendet
- US Oncology Investigational Products Center
-
Irving, Texas, Vereinigte Staaten, 75039
- Rekrutierung
- NEXT Dallas
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- NEXT Oncology
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Aktiv, nicht rekrutierend
- Virginia Cancer Specialists, PC
-
-
Washington
-
Port Angeles, Washington, Vereinigte Staaten, 98362
- Aktiv, nicht rekrutierend
- Olympic Medical Center
-
Poulsbo, Washington, Vereinigte Staaten, 98370
- Aktiv, nicht rekrutierend
- Fred Hutchinson Cancer Center Alliance Peninsula
-
Seattle, Washington, Vereinigte Staaten, 98195
- Aktiv, nicht rekrutierend
- University of Washington Medical Center
-
Seattle, Washington, Vereinigte Staaten, 98109
- Aktiv, nicht rekrutierend
- Fred Hutchinson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Part 1 and Part 2 (Closed for enrollment).
Part 3 Key Inclusion Criteria:
- Histological or cytological diagnosis of castration resistant prostate cancer.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0-2 with expected life expectancy of at least 6 months.
- Adequate bone marrow, renal, and liver function
Part 3 Key Exclusion Criteria:
- Prior irradiation to >25% of the bone marrow.
- QTcF interval >480 msec at screening.
- Hypertension that cannot be controlled by medications (>150/90 mmHg despite optimal medical therapy).
- Known or suspected hypersensitivity to PF 06821497 or any components or enzalutamide (CRPC)
- Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease or previous gastric resection or lap band surgery.
- Current use or anticipated need for food or drugs that are known strong and moderate CYP3A4/5 inducers or inhibitors
- Prior enzalutamide within the last 4 weeks
- DDI SUBSTUDY:
- history of CHF or evidence of ventricular dysfunction
- fructose intolerance
- coadministration of CYP3A4 substrates
- Any history of prior malignancies, except for carcinoma in situ or non-melanoma skin cancer, prior non-hematologic malignancies >= 3 years before randomization with no subsequent recurrence or progression, Stage 0 or 1 non-hematologic cancer < 3 years before randomization that has a remote probability of recurrence or progression.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Dose Escalation (Part 1A)
Participants with SCLC, CRPC and FL will receive mevrometostat at escalating dose levels |
Oral continuous
Andere Namen:
|
|
Experimental: Dose Escalation (Part 1B)
Participants with FL will receive mevrometostat at escalating dose levels |
Oral continuous
Andere Namen:
|
|
Experimental: Dose Escalation (Part 1C)
Participants with mCRPC will receive mevrometostat at escalating dose levels. |
Oral continuous
Andere Namen:
|
|
Experimental: Dose Escalation (Part 2A)
Participants with mCRPC and SCLC will receive mevrometostat at escalating dose levels in combination with SOC. |
Oral continuous
Andere Namen:
Oral continuous
Andere Namen:
|
|
Experimental: Dose Expansion (Part 2B)
Participants with CRPC will receive mevrometostat in combination with SOC or SOC alone. |
Oral continuous
Andere Namen:
Oral continuous
Andere Namen:
|
|
Experimental: Japan Cohort
Participants with CRPC will receive mevrometostat at one or two doses |
Oral continuous
Andere Namen:
|
|
Experimental: China cohort
Participants will receive mevrometostat at one or two doses |
Oral continuous
Andere Namen:
|
|
Experimental: Dose Expansion (Part 2C)
Participants with mCRPC will receive mevrometostat at a different dose/dosing regimen than that of Part 2B in combination with SOC |
Oral continuous
Andere Namen:
Oral continuous
Andere Namen:
|
|
Experimental: BE Substudy
In the assessment phase, each enrolled participant will receive single doses of the 2 different mevrometostat formulations in 3 periods with alternating dosing and washout between each dose. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Andere Namen:
Oral continuous
Andere Namen:
|
|
Experimental: DDI Substudy
The DDI substudy assessment phase will consist of 2 Cohorts, Cohort 1 (monotherapy cohort) and Cohort 2 (combination cohort). In the Cohort 1 assessment phase, each enrolled participant will receive a combination of mevrometostat and itraconazole based on preset schedule. In the Cohort 2 assessment phase, each enrolled participant will receive a combination of mevrometostat, enzalutamide, and itraconazole based on preset schedule. In the maintenance phase, each participant will receive mevrometostat 2 times a day and enzalutamide 1 time a day. |
Oral continuous
Andere Namen:
Oral continuous
Andere Namen:
Oral solution
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Percentage of patients with dose limiting toxicities (DLTs) to determine the maximum tolerated dose (MTD)
Zeitfenster: Baseline up to 90 days
|
First cycle DLTs will be utilized to determine the MTD |
Baseline up to 90 days
|
|
Overall safety profile including adverse events
Zeitfenster: Baseline up to approximately 2 years
|
Adverse Events will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version [4.03]) |
Baseline up to approximately 2 years
|
|
Preliminary efficacy determination as evaluated by disease specific response criteria
Zeitfenster: Through study completion, approximately 2 years past last patient first visit.
|
Objective response using Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC). Progression-free survival in Part 2B in patients with CRPC. |
Through study completion, approximately 2 years past last patient first visit.
|
|
Overall safety profile including laboratory abnormalities
Zeitfenster: Baseline up to approximately 2 years
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version [4.03]), and timing. |
Baseline up to approximately 2 years
|
|
Overall safety profile including vital signs
Zeitfenster: Baseline up to approximately 2 years
|
Vital sign changes from baseline including blood pressure, heart rate, ECG changes. |
Baseline up to approximately 2 years
|
|
Evaluate time to event mevrometostat and enzalutamide vs enzalutamide alone including radiographic prgression free survival
Zeitfenster: Baseline until disease progression or death or through study completion (approx 2 years)
|
PCWG3 |
Baseline until disease progression or death or through study completion (approx 2 years)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Evaluate time to event anti-tumor activity of mevrometostat including progression-free survival (PFS), PSA50, Duration of Response (DoR), Time to first skeletal related event and Time to symptomatic skeletal related event, depending on tumor type.
Zeitfenster: Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
Time to event endpoints based on Response Evaluation Criteria in Lymphoma (RECIL) for lymphoma, Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for solid tumors including Small Cell Lung Cancer (SCLC) and Prostate Cancer Working Group 3 (PCWG3) for Castration Resistant Prostate Cancer (CRPC) |
Baseline and every 21 days through time of confirmed disease progression, unacceptable toxicity, or through study completion, approximately 2 years.
|
|
Evaluate overall survival
Zeitfenster: Baseline up to approximately 2 years
|
Median time to death proportion of patients alive at 6 months, 1 year, and 2 years. |
Baseline up to approximately 2 years
|
|
Pharmacokinetic Parameters: Maximum Observed Plasma Concentration (Cmax)
Zeitfenster: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Zeitfenster: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Area Under the Curve (AUC)
Zeitfenster: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Oral Clearance (CL/F)
Zeitfenster: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Apparent Volume of Distribution (Vz/F)
Zeitfenster: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Single dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Pharmacokinetic Parameters: Plasma Decay Half-Life (t1/2)
Zeitfenster: At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
Singe dose and multiple dose PK will be calculated as data permits |
At specific timepoints from Cycle 1 day 1 to End of Treatment visit
|
|
Evaluate the impact of mevrometostat on patient reported outcomes.
Zeitfenster: At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
Quality of Life and Time to Functional Status Deterioration as assessed by FACT-P. |
At specific time-points from Cycle 1 Day 1 to End of Treatment visit.
|
|
Impact of mevrometostat in combination with enzalutamide, enzalutamide alone and mevrometostat alone on symptoms and symptomatic toxicity
Zeitfenster: At specific time points from Cycle1 Day 1 to end of treatment
|
Questionnaire customized from PRO-CTCAE. |
At specific time points from Cycle1 Day 1 to end of treatment
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Pfizer CT.gov Call Center, Pfizer
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen nach Standort
- Neubildungen
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Erkrankungen der Atemwege
- Neubildungen nach histologischem Typ
- Lungenkrankheit
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Lungentumoren
- Lymphatische Erkrankungen
- Lymphoproliferative Erkrankungen
- Immunproliferative Erkrankungen
- Lymphom, Non-Hodgkin
- Lymphom
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Wiederauftreten
- Kleinzelliges Lungenkarzinom
- Lymphom, follikulär
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Azolen
- Triazoles
- Piperazines
- Itraconazol
- Enzalutamid
- PF06821497
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- C2321001
- 2023-509179-18-00 (Registrierungskennung: CTIS (EU))
- EZH2 (Andere Kennung: Alias Study Number)
- 2023 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .